{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:20Z","timestamp":1792000820997,"version":"4.4.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>CR6-interacting factor 1 (CRIF1) is a nuclear transcriptional regulator and a mitochondrial inner membrane protein. Although serious modifications of the tissue architecture of the small intestine have been reported in CRIF1-deficient mice, how this may affect the development of inflammatory bowel disease (IBD) remains unclear. We investigated the effects of CRIF1 on mice with colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In DSS-induced colitis mice administered p3XFLAG-CMV-10-CRIF1, clinical symptoms were evaluated. Mitochondrial morphology in the intestinal tissues of colitis mice and UC patients was observed by electron microscopy. Level of CRIF1 in the splenic mitochondria of colitis mice or human PBMCs were investigated by western blot or real-time PCR, and the amount of IL-17 in the supernatant of healthy PBMCs co-cultured with CRIF1-overexpressing mitochondria was investigated by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overexpression of CRIF1 attenuated the severity of colitis, alleviated weight loss, and intestinal shortening. Moreover, overexpression of CRIF1 significantly reduced the levels of proinflammatory and necroptosis-related factors in colon and inhibited intestinal fibrosis. The intestines of these mice showed a reduced level of CRIF1 and altered mitochondrial morphology. Transplantation of CRIF1-overexpressed mitochondria into mice with colitis alleviated disease severity. Patients with ulcerative colitis exhibited decreased CRIF1 levels with dysfunctional mitochondria in inflamed colonic tissue. CRIF1-overexpressing mitochondria inhibited IL-17 production in PBMCs from healthy control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings demonstrate that CRIF1 alleviates IBD by suppressing inflammation and fibrosis by improving mitochondrial function. Improving mitochondrial function through CRIF1 may be a potential therapeutic strategy for IBD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1618012","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:10:44Z","timestamp":1753935044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["CRIF1 gene therapy ameliorates inflammatory bowel disease by suppressing TH17 cells and fibrosis through mitochondrial function regulation"],"prefix":"10.3389","volume":"16","author":[{"given":"Jin-Sil","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yeon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Yeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungCheon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeongWon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-La","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i30.4807","article-title":"Etiopathogenesis of inflammatory bowel diseases","volume":"12","author":"Danese","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234535","article-title":"Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00054725-200401000-00009","article-title":"Medical therapy for Crohn\u2019s disease strictures","volume":"10","author":"Van Assche","year":"2004","journal-title":"Inflammation Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1103713","article-title":"The epidemiology of inflammatory bowel disease: Clues to pathogenesis","volume":"10","author":"Borowitz","year":"2022","journal-title":"Front Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd1986","article-title":"Evolving knowledge and therapy of inflammatory bowel disease","volume":"5","author":"Korzenik","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MIB.0000000000000955","article-title":"An overview of the innate and adaptive immune system in inflammatory bowel disease","volume":"23","author":"Choy","year":"2017","journal-title":"Inflammation Bowel Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i28.3635","article-title":"Cellular and molecular mechanisms of intestinal fibrosis","volume":"18","author":"Speca","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41467-018-07841-3","article-title":"Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response","volume":"10","author":"Haberman","year":"2019","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3390\/cells10061349","article-title":"Targeting mitochondrial damage as a therapeutic for ileal crohn\u2019s disease","volume":"10","author":"Alula","year":"2021","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy095","article-title":"Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern released during active IBD","volume":"24","author":"Boyapati","year":"2018","journal-title":"Inflammation Bowel Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21944","article-title":"Mitochondria at the interface between danger signaling and metabolism: role of unfolded protein responses in chronic inflammation","volume":"18","author":"Rath","year":"2012","journal-title":"Inflammation Bowel Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601986","article-title":"Crif1 is a novel transcriptional coactivator of STAT3","volume":"27","author":"Kwon","year":"2008","journal-title":"EMBO J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.012","article-title":"CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane","volume":"16","author":"Kim","year":"2012","journal-title":"Cell Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.059840","article-title":"Essential role of CR6-interacting factor 1 (Crif1) in E74-like factor 3 (ELF3)-mediated intestinal development","volume":"284","author":"Kwon","year":"2009","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13042","article-title":"CR6-interacting factor 1 controls autoimmune arthritis by regulation of signal transducer and activator of transcription 3 pathway and T helper type 17 cells","volume":"156","author":"Park","year":"2019","journal-title":"Immunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03214.x","article-title":"Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice","volume":"146","author":"Ito","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2011.01.022","article-title":"Cordyceps militaris extract suppresses dextran sodium sulfate-induced acute colitis in mice and production of inflammatory mediators from macrophages and mast cells","volume":"134","author":"Han","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.06.018","article-title":"The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism","volume":"39","author":"Murphy","year":"2013","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e16","article-title":"Inhibition of RIPK3 pathway attenuates intestinal inflammation and cell death of inflammatory bowel disease and suppresses necroptosis in peripheral mononuclear cells of ulcerative colitis patients","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41467-018-03998-z","article-title":"Reduced oxidative capacity in macrophages results in systemic insulin resistance","volume":"9","author":"Jung","year":"2018","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.42091","article-title":"B cell-specific deletion of CR6-interacting factor 1 drives lupus-like autoimmunity by activation of interleukin-17, interleukin-6, and pathogenic follicular helper T cells in a mouse model","volume":"74","author":"Park","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0326-4","article-title":"Cell death in the gut epithelium and implications for chronic inflammation","volume":"17","author":"Patankar","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162701","article-title":"Epithelial Gab1 calibrates RIPK3-dependent necroptosis to prevent intestinal inflammation","volume":"8","author":"Xu","year":"2023","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133264","article-title":"Gut epithelial TSC1\/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer","volume":"130","author":"Xie","year":"2020","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.184","article-title":"CR6-interacting factor 1 is a key regulator in Abeta-induced mitochondrial disruption and pathogenesis of Alzheimer\u2019s disease","volume":"22","author":"Byun","year":"2015","journal-title":"Cell Death Differ"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219422","article-title":"Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319523","article-title":"Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis","volume":"69","author":"Jackson","year":"2020","journal-title":"Gut"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-010-0474-x","article-title":"Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitis","volume":"342","author":"Sifroni","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s40168-023-01686-9","article-title":"Interplay of gut microbiota and host epithelial mitochondrial dysfunction is necessary for the development of spontaneous intestinal inflammation in mice","volume":"11","author":"Alula","year":"2023","journal-title":"Microbiome"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/antiox12122105","article-title":"Mitochondrial stress links environmental triggers with pro-inflammatory signaling in crohn\u2019s disease","volume":"12","author":"Martin-Reyes","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.12.012","article-title":"Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial","volume":"134","author":"Lewis","year":"2008","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"ltaa002","DOI":"10.1093\/immadv\/ltaa002","article-title":"The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis","volume":"1","author":"Gwyer Findlay","year":"2021","journal-title":"Immunother Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15 25 1","DOI":"10.1002\/0471142735.im1525s104","article-title":"Dextran sulfate sodium (DSS)-induced colitis in mice","volume":"104","author":"Chassaing","year":"2014","journal-title":"Curr Protoc Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:10:44Z","timestamp":1753935044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1618012"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1618012","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"1618012"}}